
Carfilzomib
CAS No. 868540-17-4
Carfilzomib ( PR 171 | PR171 | PR-171 )
产品货号. M16308 CAS No. 868540-17-4
一种有效的、高选择性的蛋白酶体胰凝乳蛋白酶样活性抑制剂,IC50 为 6 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥389 | 有现货 |
![]() ![]() |
10MG | ¥551 | 有现货 |
![]() ![]() |
25MG | ¥786 | 有现货 |
![]() ![]() |
50MG | ¥1126 | 有现货 |
![]() ![]() |
100MG | ¥1531 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Carfilzomib
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种有效的、高选择性的蛋白酶体胰凝乳蛋白酶样活性抑制剂,IC50 为 6 nM。
-
产品描述A potent, highly selective inhibitor chymotrypsin-like activity of proteasome with IC50 of 6 nM; weakly inhibits caspase-like and trypsin-like activities in cellular assays (IC50150-200 nM), also inhibits the chymotrypsin-like activity of the immunoproteasome (IC50=33 nM); accumulates proteasome substrates and induces cell cycle arrest and/or apoptosis; shows antitumor efficacy in vivo.Blood Cancer Approved.
-
体外实验——
-
体内实验——
-
同义词PR 171 | PR171 | PR-171
-
通路Proteasome/Ubiquitin
-
靶点Proteasome
-
受体Proteasome
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number868540-17-4
-
分子量719.9099
-
分子式C40H57N5O7
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESCC(C)C[C@H](NC([C@@H](NC(CN1CCOCC1)=O)CCC2=CC=CC=C2)=O)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC(C)C)C([C@]4(C)OC4)=O)=O)=O.
-
化学全称L-Phenylalaninamide, (αS)-α-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kuhn DJ, et al. Blood. 2007 Nov 1;110(9):3281-90.
2. Parlati F, et al. Blood. 2009 Oct 15;114(16):3439-47.
3. O'Connor OA, et al. Clin Cancer Res. 2009 Nov 15;15(22):7085-91.
4. Demo SD, et al. Cancer Res. 2007 Jul 1;67(13):6383-91.